Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria

Show simple item record

dc.contributor.author Ribeiro, Artur Beltrame [UNIFESP]
dc.contributor.author Gavras, Haralambos [UNIFESP]
dc.date.accessioned 2015-06-14T13:32:04Z
dc.date.available 2015-06-14T13:32:04Z
dc.date.issued 2006-04-01
dc.identifier http://dx.doi.org/10.1590/S0004-27302006000200019
dc.identifier.citation Arquivos Brasileiros de Endocrinologia & Metabologia. Sociedade Brasileira de Endocrinologia e Metabologia, v. 50, n. 2, p. 327-333, 2006.
dc.identifier.issn 0004-2730
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/3028
dc.description.abstract Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago. During this period they were evaluated not only in terms of efficacy and safety but also in several large studies with clinical outcomes. They are efficacious in all clinical forms of hypertension and are effective also in all ethnic groups. Cardiovascular and renal protection in proteinuric diabetic nephropathy beyond blood pressure reduction was proved in major clinical studies: Losartan Intervention For Endpoint reduction in hypertension study (LIFE), Reduction of Endpoint in Non-Insulin dependent Diabetes Mellitus with the AII Antagonist Losartan (RENAAL) and Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT). Their blood pressure independent protective effect is also mentioned by the blockade of AT1 receptor. As a class AIIs have a tolerability profile similar to placebo. en
dc.description.abstract Os antagonistas da angiotensina II (AAIIs) foram introduzidos para o tratamento da hipertensão arterial há cerca de 10 anos. Durante esse período eles foram avaliados não apenas em termos de eficácia e segurança, mas também em vários estudos grandes com desfechos clínicos. Os AAIIs são eficazes em todas as formas clínicas de hipertensão e, também, em todos os grupos étnicos. Os principais estudos clínicos em pacientes diabéticos com nefropatia e proteinúia comprovaram, além da redução da pressão arterial, proteção cardiovascular e renal: Losartan Intervention For Endpoint reduction in hypertension study (LIFE), Reduction of Endpoint in Non-Insulin dependent Diabetes Mellitus with the AII Antagonist Losartan (RENAAL) e Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT). O seu efeito protetor independente da pressão sanguínea também é mencionado pelo bloqueio do receptor AT1. Os AAIIs, como classe medicamentosa, apresentam um perfil de tolerabilidade semelhante ao placebo. pt
dc.format.extent 327-333
dc.language.iso eng
dc.publisher Sociedade Brasileira de Endocrinologia e Metabologia
dc.relation.ispartof Arquivos Brasileiros de Endocrinologia & Metabologia
dc.rights Acesso aberto
dc.subject Hypertension en
dc.subject Cardiovascular disease en
dc.subject Diabetes mellitus en
dc.subject Angiotensin II antagonists en
dc.subject Stroke en
dc.subject End-stage renal disease en
dc.subject Losartan en
dc.subject Hipertensão pt
dc.subject Doença cardiovascular pt
dc.subject Diabetes mellitus pt
dc.subject Antagonistas de angiotensina II pt
dc.subject Acidente vascular cerebral pt
dc.subject Doença renal terminal pt
dc.subject Losartana pt
dc.title Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria en
dc.title.alternative Antagonistas da angiotensina II: experiência clínica com o tratamento da hipertensão, prevenção de desfechos cardiovasculares e proteção renal na nefropatia diabética e proteinúria pt
dc.type Artigo
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution University School of Medicine Hypertension and Atherosclerosis Section
dc.description.affiliation UNIFESP Fundação Oswaldo Ramos Hospital do Rim e Hipertensão
dc.description.affiliation University School of Medicine Hypertension and Atherosclerosis Section
dc.description.affiliationUnifesp UNIFESP, Fundação Oswaldo Ramos Hospital do Rim e Hipertensão
dc.identifier.file S0004-27302006000200019.pdf
dc.identifier.scielo S0004-27302006000200019
dc.identifier.doi 10.1590/S0004-27302006000200019
dc.description.source SciELO



File

Name: S0004-27302006000200019.pdf
Size: 75.60Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account